Safety and Tolerability of Pirfenidone in Acute Pancreatitis

The study is a Randomized Pilot clinical trial evaluating safety and tolerability ofpirfenidone in patients with predicted moderately severe to severe acute pancreatitis.There are built in secondary end‐points for efficacy. The patients with acutepancreatitis, who present within 48h of establishment of the diagnosis, will be screenedfor exclusion and inclusion criteria and consented for the clinical trial. Patients withbe randomized into placebo or pirfenidone arm and followed daily in‐person, while inhospital, and by telephone once discharged from the hospital (weekly for 4 weeks, thenmonthly for up to 6 months) for study end points.